These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24647711)

  • 1. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
    Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y
    J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
    Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
    Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
    Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
    Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
    Wang X; Gattone V; Harris PC; Torres VE
    J Am Soc Nephrol; 2005 Apr; 16(4):846-51. PubMed ID: 15728778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased water intake decreases progression of polycystic kidney disease in the PCK rat.
    Nagao S; Nishii K; Katsuyama M; Kurahashi H; Marunouchi T; Takahashi H; Wallace DP
    J Am Soc Nephrol; 2006 Aug; 17(8):2220-7. PubMed ID: 16807403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
    Kapoor S; Rodriguez D; Riwanto M; Edenhofer I; Segerer S; Mitchell K; Wüthrich RP
    PLoS One; 2015; 10(4):e0125603. PubMed ID: 25927597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y; Kim J; Schrier RW; Edelstein CL
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
    Gattone VH; Wang X; Harris PC; Torres VE
    Nat Med; 2003 Oct; 9(10):1323-6. PubMed ID: 14502283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.
    Zhang T; Wang L; Xiong X; Mao Z; Wang L; Mei C
    Biol Res; 2009; 42(4):437-44. PubMed ID: 20140299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
    PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease.
    Omori S; Hida M; Fujita H; Takahashi H; Tanimura S; Kohno M; Awazu M
    J Am Soc Nephrol; 2006 Jun; 17(6):1604-14. PubMed ID: 16641154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.
    Ta MH; Schwensen KG; Foster S; Korgaonkar M; Ozimek-Kulik JE; Phillips JK; Peduto A; Rangan GK
    PLoS One; 2016; 11(10):e0164193. PubMed ID: 27723777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Exercise Protects against the Progression of Renal Cyst Growth and Dysfunction in Rats with Polycystic Kidney Disease.
    Qiu J; Sato Y; Xu L; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2021 Dec; 53(12):2485-2494. PubMed ID: 34310502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR signaling in polycystic kidney disease.
    Ibraghimov-Beskrovnaya O; Natoli TA
    Trends Mol Med; 2011 Nov; 17(11):625-33. PubMed ID: 21775207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.